SUZHOU, China – At the 3rd DIA China Drug Discovery Innovation, a director from the Ministry of Science and Technology (MOST) outlined the government's proposed plans to accelerate approvals for the collection of human genetic resources in keeping with the central government's overall strategy to support innovative drug development. Read More
BOSTON – At last week's Biopharm America meeting, Astellas Pharma Inc.'s Salim Mujais sat down with BioWorld Asia for a high-level look at the Tokyo-based firm's efforts in therapeutic areas outside of cancer. Read More
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) reported a mixed review for its annual performance for drugs and devices covering the period from July 2016 to June 2017 compared to the previous year. Although the agency approved roughly the same number of new chemical entities (NCEs) during 2016 to 2017, approval timelines rose compared to the previous year. Even so, the agency said it reviewed all drugs and devices within the specified legislated time frames. Read More
Researchers at National Taiwan University (NTU) in Taipei have developed a new stem cell-based treatment modality, which may prevent damage to the growth phase of hair follicles due to cancer therapies. The findings may lead to the first effective treatment for preventing hair loss in cancer patients. Read More
Propanc Biopharma Inc., of Melbourne, Australia, said results from recent scientific experiments provide strong indicators of PRP's therapeutic potential as a clinical approach in cancer, showing a reduction of epithelial to mesenchymal transition (EMT) markers as a consequence of PRP treatment, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of cancer stem cells. PRP, a solution for once-daily intravenous combo of pancreatic proenzymes trypsinogen and chymotrypsinogen, is advancing toward first-in-human studies. Read More
